Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | The evolution of the AML treatment paradigm

Jeffrey Lancet • 2 Sep 2021
SOHO 2021
Acute Myeloid Leukemia Leukemia Antibodies CPX-351 Cytarabine Daunorubicin Gemtuzumab ozogamicin

Jeffrey Lancet, MD, of Moffitt Cancer Center, Tampa, FL, discusses changes in the treatment landscape for acute myeloid leukemia (AML), and suggests how it may change in the future. Improvements in AML treatment have largely been driven by a better understanding of prognostic markers and genetic therapeutic targets. Dr Lancet also explains how venetoclax and hypomethylating agent (HMA)-based therapies are expected to be utilized more in the future. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

More from Jeffrey Lancet

4:48
Canakinumab with darbepoetin in patients with LR-MDS who are ESA-refractory
Jeffrey Lancet • 8 Dec 2023
5:17
COVALENT-101: investigating menin inhibition with BMF-219 for treating patients with R/R AML or ALL
Jeffrey Lancet • 8 Dec 2023
1:45
The impact of secondary-type mutations in NPM1-mutated AML
Jeffrey Lancet • 11 Dec 2021
6:57
Responses to COVID-19 vaccines in patients with AML and MDS
Jeffrey Lancet • 11 Dec 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals